Which ASX cybersecurity stocks are best positioned to benefit from the surge in cyber spending?
Rising cyber threats, stricter regulations, and the rapid shift to cloud and AI systems are driving a sharp increase in global cybersecurity spending, and the ASX is starting to reflect that trend. The Australian cybersecurity market alone is expected to grow from about A$8.4 billion in 2025 to nearly A$19.6 billion by 2030, highlighting the scale of opportunity ahead.
Is 4DMedical (ASX: 4DX) the Next High-Growth MedTech Breakout or a Funding Risk?
4DMedical Limited is an Australian medtech company developing lung imaging software that turns standard scans into functional insights. It has strong growth potential through scalable products like CT:VQ, but remains speculative due to ongoing cash burn, reliance on adoption, and funding risk.
CETTIRE's (ASX: CTT) share price is back to all time low levels, is it time to buy?
Recent tariff changes and trade frictions have disrupted that advantage and slowed growth. However, CETTIRE’s flexible, low-cost structure suggests its core model remains intact, leaving the company with meaningful long-term profit potential despite the current uncertainty around customer growth and demand.
.webp&w=828&q=75)
Invictus Energy (ASX: IVZ): Billion-Barrel Potential or Bust?
Invictus Energy is an early-stage oil and gas explorer in Zimbabwe with large but unproven resource potential. With no revenue and heavy funding needs, the stock offers significant upside if discoveries succeed, but remains a high-risk, news-driven investment.
How much higher can the breakout in Liontown's (ASX: LTR) share price take it?
Liontown Resources has rallied on stronger lithium prices, improving production at Kathleen Valley, and a healthier balance sheet after reducing debt. Rising EV and battery demand plus new offtake deals have lifted sentiment. The stock is now approaching key resistance around A$2.20, where the next breakout or pullback will likely be decided.
Massive Volume Surge in Botanix Pharmaceuticals (ASX: BOT): Is it finally finding a bottom?
Botanix Pharmaceuticals has seen a sharp volume spike after a major share price decline, hinting at possible bottoming. While Sofdra sales are growing and funding has improved liquidity, the stock remains in a downtrend, with any recovery dependent on stronger fundamentals and a break above key resistance.